Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

azine). Alexza is developing AZ-001 to treat patients suffering from acute migraine headaches. Alexza requested an end of Phase 2 meeting with the FDA during the second quarter of 2008 and has been granted this meeting for the third quarter of 2008.

-- AZ-104 (Staccato loxapine). Alexza is developing AZ-104 to treat patients suffering from acute migraine headaches. AZ-104 is a lower dose version of AZ-004. In March 2008, the Company announced initial results of an in-clinic, multi-center randomized, double-blind, single administration, placebo controlled Phase 2a proof-of-concept clinical trial in 168 migraine patients with or without aura. Three doses of AZ-104 (1.25, 2.5 and 5 mg) were evaluated against placebo in the clinical trial. Using the IHS 4-point rating scale, the primary efficacy endpoint was pain-relief response at 2 hours post-administration. AZ-104 met the primary efficacy endpoint of the clinical trial for the two highest doses of the drug compared to placebo. Statistically significant improvements in pain response were observed in 76.7% of patients at the 5 mg dose (p= 0.02), 79.1% of patients at the 2.5 mg dose (p = 0.01) and 67.4% of patients at the 1.25 mg dose (p = 0.18), compared to 51.3% of patients receiving placebo. Using survival analysis for pain relief response, all three dose groups were statistically superior (p < 0.05) to placebo during the 4-hour post-treatment time period that the patients remained in the clinic.

Alexza's original IND for Staccato loxapine was filed with the Division of Neuropharmacological Drug Products of the FDA. In July 2005 the FDA reorganized this division into two new divisions, the Division of Psychiatry Products, or DPP, and the Division of Neurology Products, or DNP. The Staccato loxapine IND was transferred to the DPP, as the AZ-004 development program is for a psychiatric indication. Under that IND, Alexza was allowed to conduct the first patient study in migraine patients, the Phase 2a proo
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Today, Rhodes Pharmaceuticals L.P. announced that ... indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) ... The announcement comes just one ... U.S. Food and Drug Administration (FDA). ... methylphenidate capsule with an onset of effect of ...
(Date:5/21/2015)... , May 21, 2015 ... has announced the addition of the ... (Ankle Replacement, Digit Replacement, Elbow Replacement, Hip ... to 2019" report to their offering. ... knee replacement was valued at $4,470.9 million ...
(Date:5/21/2015)... , May 21, 2015  CryoLife, Inc. (NYSE: ... processing company focused on cardiac and vascular surgery, announced ... quarterly cash dividend for the second quarter 2015 of ... cash dividend of $0.03 per share will be paid ... record as of June 12, 2015.  The ex-dividend date ...
Breaking Medicine Technology:Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2
... AMSTERDAM, December 2 Amsterdam Molecular,Therapeutics ... gene therapy,announced today a number of management changes. Piers ... December 1, 2009. Hans,Preusting, PhD (age 47), Director Process ... and Project Management, also,effective December 1. These changes reflect ...
... BEACH, Calif., Dec. 1 Reproductive Partners Medical Group, ... Program to provide a financial incentive for patients with ... to consider reducing the chance of twins by transferring ... reproductive technology today is reducing the number of multiple ...
Cached Medicine Technology:AMT Announces Management Changes in Light of Refocused Strategy 2AMT Announces Management Changes in Light of Refocused Strategy 3Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2
(Date:5/25/2015)... 2015 Tunstall Americas announces major investment ... level of service to its Medical Answering Service customers. ... restructuring of resources, Tunstall now provides a seamless transition ... Answering Service to ensure superior patient satisfaction. ... invested over $10 million in expanded facilities and the ...
(Date:5/24/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... many patients for concerns about hair loss. Although it ... is clear that there are environmental factors such as ... that can contribute. Since they offer a comprehensive approach ... the peri and post-menopausal woman, they can help patients ...
(Date:5/24/2015)... York, New York (PRWEB) May 24, 2015 ... testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled ... the progress of the multidistrict litigation. According to ... Northern District of Illinois, the Conference will be ... (In re: Testosterone Replacement Therapy Product Liability Litigation ...
(Date:5/24/2015)... May 24, 2015 A report ... that the single best option for avoiding cardiovascular disease ... fitness level was the single most powerful predictor of ... such as diabetes and family history of premature death ... lifelong heart and lung fitness. , The Importance of ...
(Date:5/23/2015)... 23, 2015 On Wednesday, May 20, ... company has been the target of a sophisticated cyberattack,” ... the company’s ongoing Information Technology (IT) security efforts in ... , The most notable attack on health insurers was ... the nation’s second largest health insurer, revealed that they ...
Breaking Medicine News(10 mins):Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4
... It,s known that people who live or work in rural ... injuries compared to those in more urban environments. But while ... rates, new research suggests that limited access to early, high-quality ... factor. Researchers from St. Michael,s in Toronto looked at ...
... study by doctors at Mount Sinai Hospital in New ... an offshoot of medical tourism, which focuses solely on ... the practice of transplant tourism where patients travel to ... their transplantation. These transplant tourists may be subject ...
... ... ... National Heart Month, and Oldways and the Mediterranean Foods Alliance offer ... the Mediterranean region. Thousands of scientific studies (and the American Heart Association!) declare the Mediterranean ...
... chance of pregnancy by up to 50%, researchers say, , ... to a common chemical that,s used as a flame retardant ... , The chemicals, called PBDEs (polybrominated diphenyl ethers), are found ... carpets, plastics and other common household items and have been ...
... chemo-surgery regimen, researchers say , TUESDAY, Jan. 26 ... promise against locally advanced rectal cancer. , The ... rectal cancer, meaning they have a high likelihood ... receiving standard chemotherapy and optimum surgery. , For ...
... ... Interaction Associates details three essential actions for leaders to move an organization from conflict ... when not handled successfully. To download the white paper, go here: http://bit.ly/8ZcCNt ... Cambridge, ...
Cached Medicine News:Health News:More than 50 percent of injury-related deaths in rural Ontario occur before patients reach hospital 2Health News:More than 50 percent of injury-related deaths in rural Ontario occur before patients reach hospital 3Health News:Transplant tourism poses ethical dilemma for US doctors 2Health News:Transplant tourism poses ethical dilemma for US doctors 3Health News:10 Healthy Med Ways to Show Your Heart Some Love 2Health News:10 Healthy Med Ways to Show Your Heart Some Love 3Health News:Flame-Retardant Chemical Linked to Conception Problems 2Health News:Flame-Retardant Chemical Linked to Conception Problems 3Health News:Intensive Rectal Cancer Treatment Shows Promise 2Health News:From Conflict to Consensus: Interaction Associates Outlines How Leaders Can Achieve Successful Alignment and Implementation 2Health News:From Conflict to Consensus: Interaction Associates Outlines How Leaders Can Achieve Successful Alignment and Implementation 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: